Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential
- PMID: 15501953
- DOI: 10.1158/1078-0432.CCR-04-0275
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential
Abstract
Purpose: We have identified a subset of patients exhibiting extended survival with metastases from androgenindependent prostate cancer of which the principal site of progression was the tumor primary. The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients.
Experimental design: A 105 core tissue microarray was constructed from primary tumor samples from 16 patients, with matched lymph node metastases in 5 cases. Immunohistochemistry was used to evaluate selected biomarkers associated with prostate cancer progression. Standard statistical methodologies were used to compute the distribution of time to progression and overall survival associations between pairs of biomarkers. Hierarchical clustering was done between groups of biomarkers, and we devised new methods to assess homogeneity of biomarker expression.
Results: The median interval from diagnosis to salvage surgery was 65 months. The profile of biomarker expression was notable for virtual absence of neuroendocrine features, high CD10, low matrix metalloproteinase (MMP)-9, high E-cadherin expression, and high membranous beta-catenin. The mean proliferative index was 12.1 +/- 10.1%, and the mean apoptotic index was 3.48 +/- 2.22%, and there was a significant correlation between these indices. Expression of the epidermal growth factor receptor was associated with phospho-AKT and proliferative index but inversely associated with phospho-STAT3.
Conclusions: The cohort of prostate cancer patients, characterized by locally aggressive disease rather than lethal metastatic progression, was associated with a distinctive biomarker signature. The biomarker profile was, in general, more consistent with low-grade prostate cancer exhibiting local growth rather than metastatic progression. Ongoing studies will establish whether this unique subset of patients can be identified prospectively.
Similar articles
-
Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.Prostate. 2002 May 1;51(2):84-97. doi: 10.1002/pros.10063. Prostate. 2002. PMID: 11948963
-
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.J Clin Oncol. 2011 Jun 20;29(18):2574-81. doi: 10.1200/JCO.2010.33.2999. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606419 Free PMC article. Clinical Trial.
-
MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.Prostate Cancer Prostatic Dis. 2016 Sep;19(3):242-7. doi: 10.1038/pcan.2016.11. Epub 2016 May 10. Prostate Cancer Prostatic Dis. 2016. PMID: 27165976
-
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.BMC Cancer. 2020 May 7;20(1):398. doi: 10.1186/s12885-020-06817-1. BMC Cancer. 2020. PMID: 32380981 Free PMC article.
-
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence.Clin Prostate Cancer. 2003 Jun;2(1):50-7. doi: 10.3816/cgc.2003.n.013. Clin Prostate Cancer. 2003. PMID: 15046685 Review.
Cited by
-
The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.Int J Mol Sci. 2021 Mar 30;22(7):3608. doi: 10.3390/ijms22073608. Int J Mol Sci. 2021. PMID: 33808504 Free PMC article.
-
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer.BMC Med Genomics. 2008 Jan 31;1:1. doi: 10.1186/1755-8794-1-1. BMC Med Genomics. 2008. PMID: 18237448 Free PMC article.
-
Wnt signaling in castration-resistant prostate cancer: implications for therapy.Am J Clin Exp Urol. 2014 Apr 15;2(1):27-44. Am J Clin Exp Urol. 2014. PMID: 25143959 Free PMC article.
-
N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.Int J Biochem Cell Biol. 2010 Dec;42(12):2037-46. doi: 10.1016/j.biocel.2010.09.008. Epub 2010 Sep 18. Int J Biochem Cell Biol. 2010. PMID: 20854925 Free PMC article.
-
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.BMC Med Genomics. 2010 Sep 24;3:43. doi: 10.1186/1755-8794-3-43. BMC Med Genomics. 2010. PMID: 20868494 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous